As the authors discuss, monitoring of specific immune subsets like CD103+Vγ4 cells (which can be performed upon routine endoscopic biopsy) might be a useful novel biomarker to assess disease activity in IBD. This evidence concerns the gene ITGAE and inflammatory bowel disease.